Latest fiscal year 2026 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2026, China SXT Pharmaceuticals, Inc. reported revenue of $1M, down 34.6% year over year. Operating margin was -625.9% and net margin -545.2%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from SXTC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2026 | $1M | -625.9% | -545.2% |
| FY2025 | $2M | -154.0% | -189.8% |
| FY2024 | $2M | -130.4% | -160.7% |
| FY2023 | $2M | -284.4% | -301.0% |
| FY2022 | $3M | -199.4% | -220.4% |
How does SXTC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.